{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:07:15Z","timestamp":1761059235028},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T00:00:00Z","timestamp":1313712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Potent teratogenicity limits the use of isotretinoin among females of childbearing potential (FCBP).<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To explore the current practice of dermatologists for pregnancy prevention when prescribing isotretinoin for FCBP.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold> A self\u2010administered questionnaire was distributed to 160 dermatologists attending a national conference in Riyadh, Saudi Arabia, in 2008. The survey was designed to capture the details of precautions taken by dermatologists to prevent pregnancy among isotretinoin users.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Ultimately, 134 dermatologists completed the questionnaire (84% response rate). Their mean age was 39\u2003\u00b1\u20039.5\u2003years. A total of 82 were female (65%). The median number of FCBP for whom isotretinoin was prescribed by each dermatologist during the previous 12\u2003months was two (range from 0 to 30). Of the 792 total FCBP, seven were reported to have become pregnant (incidence rate of 8.8\/1000) while on isotretinoin. Out of those seven, three women terminated the pregnancy (elective abortions: 42.7%). The majority of the dermatologists (79%) always obtained written consent and discussed teratogenic risks (98%); 44% provided written information about potential isotretinoin teratogenicity, and 30% offered printed information on contraception. Survey results also revealed that 62% recommended double contraception for FCBP, 60% always recommended pregnancy testing prior to therapy, but only 16% requested monthly pregnancy tests. In general, 62.4% avoided isotretinoin prescription to FCBP, which was independent of dermatologists\u2019 gender, years of experience, or having a previous incident of isotretinoin\u2010exposed pregnancy.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Some dermatologists still do not follow the recommendations for isotretinoin prescription to FCBP. This needs to be corrected, especially in countries with restrictions on abortion.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2011.04875.x","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T15:38:21Z","timestamp":1314113901000},"page":"1094-1098","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dermatologists\u2019 level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential"],"prefix":"10.1111","volume":"50","author":[{"given":"Khalid M.","family":"AlGhamdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Khurram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif A.","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Mandil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,8,19]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Physicians\u2019 Desk Reference","author":"Medical Economics Company","year":"1999"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38987.606701.80"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.5.686"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198510033131401"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(93)90273-A"},{"key":"e_1_2_7_7_2","first-page":"273","article-title":"Accutane Roche: risk of teratogenic effects","volume":"131","author":"Zarowny DP","year":"1984","journal-title":"Can Med Assoc J"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507133330206"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.5.563"},{"key":"e_1_2_7_10_2","unstructured":"US Food and Drug Administration.FDA and manufacturers of Accutane and its generics to implement iPLEDGE Program on March 1 2006. Web site available at:http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108605.htm[Accessed 20 Dec 2009]."},{"key":"e_1_2_7_11_2","first-page":"15","article-title":"Update on birth defects with isotretinoin","volume":"14","author":"Department of Health and Human Services","year":"1984","journal-title":"FDA Drug Bull"},{"key":"e_1_2_7_12_2","first-page":"171","article-title":"Birth defects caused by isotretinoin \u2013 New Jersey","volume":"37","author":"Centre for Disease Control and Prevention (CDC)","year":"1988","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-720X.2009.00355.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1057"},{"key":"e_1_2_7_15_2","unstructured":"Food and Drug Administration.Briefing document for iPLEDGE year one update United States Department of Health and Human Services available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007\u20104311b1\u201002\u2010ipledge.pdf[Accessed 20 Dec 2009]."},{"key":"e_1_2_7_16_2","unstructured":"DarvesB.Dermatologists frustrated with problematic iPledge program.Medscape Med News9 March 2006 [Accessed 20 Dec 2009]."},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040317"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030483"},{"key":"e_1_2_7_19_2","first-page":"339","article-title":"Pregnancy prevention among women taking isotretinoin, failure to comply with the recommendations","volume":"52","author":"Boucher N","year":"2006","journal-title":"Can Fam Physician"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2009.00516.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1783\/147118910790291019"},{"key":"e_1_2_7_22_2","unstructured":"Islamic Research Foundation International.http:\/\/www.irfi.org\/. Abortion [cited 20 Dec 2009]."},{"key":"e_1_2_7_23_2","first-page":"29","article-title":"Abortion: an Islamic ethical view","volume":"6","author":"Aramesh K","year":"2007","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-003-0783-4"},{"key":"e_1_2_7_25_2","unstructured":"Ethics of abortion. Available at;http:\/\/www.bbc.co.uk\/religion\/religions\/judaism\/jewishethics\/abortion_1.shtml[Accessed 20 Dec 2009]."},{"key":"e_1_2_7_26_2","first-page":"73","article-title":"Abortion in Islamic countries \u2013 legal and religious aspects","volume":"23","author":"Asman O","year":"2004","journal-title":"Med Law"},{"key":"e_1_2_7_27_2","unstructured":"MitchellAA Van BenekomC.Survey of Accutane\u00aeUse in Women.Brookline Mass: US Food and Drug Administration 2000. Available from:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/00\/backgrd\/3639b1c_24.pdf[Accessed 20 Dec 2009]."},{"key":"e_1_2_7_28_2","first-page":"1719","article-title":"Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program","volume":"160","author":"Atanackovic G","year":"1999","journal-title":"Can Med Assoc J"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02837.x"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2011.04875.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2011.04875.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:48:25Z","timestamp":1697356105000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2011.04875.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,19]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1365-4632.2011.04875.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2011.04875.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,19]]},"assertion":[{"value":"2011-08-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}